Cytek Biosciences, Inc.
CTKBCytek Biosciences is a leading cell analysis solutions company that develops next-generation research and clinical tools for biomedical research and clinical applications.
Earnings
Next report
Nov 4, 2026 (in 2 months)Valuation & ratios
Segments
Competitors
By market cap
By revenue growth
By net margin
Profile
Cytek Biosciences is a leading cell analysis solutions company that develops next-generation research and clinical tools for biomedical research and clinical applications. The company utilizes its proprietary Full Spectrum Profiling (FSP) technology to provide high-resolution, high-content single-cell analysis by leveraging fluorescence signatures from multiple lasers. Its platform enables scientists to phenotype and isolate rare cell populations with high sensitivity, addressing limitations in conventional flow cytometry.
A leading innovator in spectral flow cytometry that differentiates itself through high-parameter multiplexing and superior sensitivity at a lower cost for performance compared to legacy systems.
FAQ
- What is Cytek Biosciences, Inc.'s market cap?
- Cytek Biosciences, Inc. (CTKB) has a market capitalization of $640.8M and trades on NASDAQ.
- What is Cytek Biosciences, Inc.'s revenue and profitability?
- Cytek Biosciences, Inc. generated $206.7M in trailing twelve-month revenue with a net loss of $80.6M, representing a net margin of -39.0%. Gross margin stands at 53.2%, with free cash flow of -$12.1M. The latest reported period is Q2 2026.
- Who are Cytek Biosciences, Inc.'s competitors?
- Cytek Biosciences, Inc.'s key competitors include Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc.'s subsidiaries include Amnis, Guava.
- Where is Cytek Biosciences, Inc. headquartered?
- Cytek Biosciences, Inc. is headquartered in United States of America and employs approximately 637 people. It has been publicly traded since 2021.
